The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age  6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score  652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701

Importance of Threshold Concepts for Disciplinary Discussions

Date: March 26, 2018 Time: 12:00-1:00pm Location: Gertrude Ford Ballroom A-Inn at Ole Miss Dr. Barry Maid, Professor and Founding Head of Technical Communication at Arizona State, visits UM to share his research on “threshold concepts.” In the early part of the twenty-first century, British researchers Jan Meyer and Ray Land introduced the idea of threshold concepts. Essentially, threshold concepts are the ways of thinking one must possess in order to take part in disciplinary discussions. In this FDL, Dr. Maid will • define threshold concepts • provide examples of discipline-based threshold concepts • discuss ways that faculty can identify threshold concepts within their disciplines • advise faculty about implementing threshold concepts into their teaching Presenter: Barry Maid (Arizona State University) is Professor and Founding Head of Technical Communication at Arizona State University. He has written extensively about technology, independent writing programs, and program administration. His recent research focuses on threshold concepts and their assessment

A Matrix for Reconsidering, Reassessing, and Shaping E–Learning Pedagogy and Curriculum

Educational stakeholders are increasingly engaged in discussions about the effective design, distribution, and evaluation of e-learning. We invite educators to build on already existing scholarship as they make future e-learning decisions. Specifically, we combine four categories of academic scholarship from Boyer (1990) with six assessment criteria from Glassick, Huber, and Maeroff (1997) to construct a matrix that may be applied to any post-secondary learning or teaching context. We argue that while each medium in which faculty might find themselves teaching differs from others, the teaching itself, and effective teaching in general, is definable and, therefore, can be evaluated using the matrix

The IL Framework and WPA OS: Threshold Concepts and Metaliteracy

In February 2015, the Association of College and Research Libraries adopted the Framework for Information Literacy for Higher Education (IL Framework). Conceptually grounded in threshold concepts and metaliteracy, the IL Framework represents a shift away from conceiving IL as discrete and mechanical skills towards a richer and more complex understanding of it as contextual and situated—i.e., rhetorical. With increased attention within Writing Studies to threshold concepts and transfer, the IL Framework presents opportunities and challenges for faculty and librarians. The IL Framework opens the door to enhanced and richer collaborations based on IL as a more contextualized construct. The IL Framework also presents challenges to potentially alter our thinking and practices based upon an understanding of threshold concepts and metaliteracy. Produced by different disciplines, the IL Framework, the WPA Outcomes Statement, and the Framework for Success articulate shared concern with fostering learning. In this presentation we will examine threshold concepts and metaliteracy as theoretical underpinnings for the IL Framework. We will then analyze how the IL Framework aligns with the WPA Outcomes Statement and the Framework for Success in Postsecondary Education. In particular, we will discuss how the alignment potentially leads to more effective pedagogical practices

The McGraw-Hill guide writing for college, writing for life

New Yorkxliii, (927+170) p.; 24 c

Handbook for the McGraw-Hill guide : writing for college, writing for life

108 p. ; 23 cm

The McGraw-Hill guide : writing for College, Writing for Life 1 Ed

The McGraw-Hill Guide to Writing dirancang untuk membantu siswa belajar menulis lebih efektif tidak hanya di program kuliah mereka tetapi juga dalam kehidupan profesional, kewarganegaraan, dan pribadi mereka. Menggabungkan pembaca yang fleksibel, retorika, panduan penelitian, dan buku pegangan, The McGraw-Hill Guide menunjukkan kepada siswa cara menetapkan tujuan untuk tulisan mereka, menggunakan strategi penyusunan yang efektif untuk mencapai tujuan tersebut, dan untuk menilai kemajuan mereka menuju pencapaiannya. Berdasarkan gagasan bahwa penulis yang efektif adalah komunikator yang kuat dalam konteks apa pun, The McGraw-Hill Guide to Writing menekankan keterampilan yang ditetapkan oleh Pernyataan Hasil Administrator Program Penulisan yang membentuk dasar praktik penilaian pada program penulisan di seluruh negeri - pengetahuan retorika, pemikiran kritis, proses penulisan, dan konvensi. Keterampilan ini membentuk dasar instruksi di setiap bab penugasan dan di seluruh teks

Correction to: Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

International audienceIn this article, the name of the GLORIA-AF investigator Anastasios Kollias was given incorrectly as Athanasios Kollias in the Acknowledgements. The original article has been corrected

Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry

Background: Previous studies suggested potential ethnic differences in the management and outcomes of atrial fibrillation (AF). We aim to analyse oral anticoagulant (OAC) prescription, discontinuation, and risk of adverse outcomes in Asian patients with AF, using data from a global prospective cohort study. Methods: From the GLORIA-AF Registry Phase II-III (November 2011-December 2014 for Phase II, and January 2014-December 2016 for Phase III), we analysed patients according to their self-reported ethnicity (Asian vs. non-Asian), as well as according to Asian subgroups (Chinese, Japanese, Korean and other Asian). Logistic regression was used to analyse OAC prescription, while the risk of OAC discontinuation and adverse outcomes were analysed through Cox-regression model. Our primary outcome was the composite of all-cause death and major adverse cardiovascular events (MACE). The original studies were registered with ClinicalTrials.gov, NCT01468701, NCT01671007, and NCT01937377. Findings: 34,421 patients were included (70.0 ± 10.5 years, 45.1% females, 6900 (20.0%) Asian: 3829 (55.5%) Chinese, 814 (11.8%) Japanese, 1964 (28.5%) Korean and 293 (4.2%) other Asian). Most of the Asian patients were recruited in Asia (n = 6701, 97.1%), while non-Asian patients were mainly recruited in Europe (n = 15,449, 56.1%) and North America (n = 8378, 30.4%). Compared to non-Asian individuals, prescription of OAC and non-vitamin K antagonist oral anticoagulant (NOAC) was lower in Asian patients (Odds Ratio [OR] and 95% Confidence Intervals (CI): 0.23 [0.22-0.25] and 0.66 [0.61-0.71], respectively), but higher in the Japanese subgroup. Asian ethnicity was also associated with higher risk of OAC discontinuation (Hazard Ratio [HR] and [95% CI]: 1.79 [1.67-1.92]), and lower risk of the primary composite outcome (HR [95% CI]: 0.86 [0.76-0.96]). Among the exploratory secondary outcomes, Asian ethnicity was associated with higher risks of thromboembolism and intracranial haemorrhage, and lower risk of major bleeding. Interpretation: Our results showed that Asian patients with AF showed suboptimal thromboembolic risk management and a specific risk profile of adverse outcomes; these differences may also reflect differences in country-specific factors. Ensuring integrated and appropriate treatment of these patients is crucial to improve their prognosis. Funding: The GLORIA-AF Registry was funded by Boehringer Ingelheim GmbH